LAST CHANCE to participate in our current survey
By late yesterday nearly 600 men had completed our recent survey and most of them had expressed some degree of interest in participating in the quality of life trial we will be initiating soon. Again,...
View ArticleProstvac in the treatment of prostate cancer: an update
As many readers will remember, Prostvac is an active immunotherapeutic vaccine that — some years ago — had shown promising results in a randomized Phase II clinical trial. A multinational, three-arm,...
View ArticlePatient satisfaction at 24 months after treatment for localized prostate cancer
The ability to “manage” patients’ satisfaction with their care in the treatment of localized prostate cancer is challenging — for patients, for caregivers, for physicians, and for health systems. While...
View ArticleJ&J to seek approval of apalutamide in treatment of mCSPC
According to a media release issued yesterday by Johnson & Johnson, its Janssen Pharmaceuticals division has just submitted an application to the U.S. Food and Drug Administration for the approval...
View ArticleUPDATE … the new PCa Social Network PLUS app
A couple of weeks ago (see here) we had first told you about the launch of the new PCa Social Network PLUS app that allows mobile access to a new social netowrk (and a clinical trial of its effects)...
View ArticleAdjuvant chemotherapy does NOT improve BDFS rates in men with intermediate-...
With the third Advanced Prostate Cancer Consensus Conference (APCCC) due to start here in Basel, Switzerland, this morning, there is an important new set of data that will help to inform some of the...
View ArticleHigh-dose vitamin D: negative results from a randomized clinical trial
Data from a recently published, Canadian, clinical trial of high-dose vitamin D as a method to strengthen bones in healthy adults who do not have osteoporesis have had significant and unexpectedly...
View ArticleThe first-line treatment of locally advanced prostate cancer (clinical stage T3)
Does radical prostatectomy (with or without external beam radiation therapy) improve prostate-cancer specific survival by comparison with primary radiation treatment and androgen deprivation therapy...
View ArticleSipuleucel-T in management of favorable-risk prostate cancer: the ProVent trial
At the end of last year, Dendreon announced that the Phase III ProVent trial of sipuelucel-T (Provenge) in the treatment of men with relatively lower-risk forms of prostate cancer (as compared to...
View ArticleData from HERO trial reported — at virtual ASCO and in NEJM
The results of the Phase III HERO trial of relugolix — the first oral LHRH antagonist for treatment of advanced prostate cancer — have now been reported in the New England Journal of Medicine (NEJM)...
View ArticleIpatasertib meets one of two primary endpoints in Phase III trial
According to a media release issued by Roche earlier this morning, the company’s investigational drug known as ipatasertib met one but not both of the two primary endpoints in a randomized,...
View ArticleNeoadjuvant CHT + surgery for men with high-risk, localized prostate cancer
Eastham et al. have recently reported — in the Journal of Clinical Oncology — results from a randomized Phase III trial of the surgical treatment of men with high-risk forms of localized prostate...
View ArticleOnvansertib in treatment of abiraterone-resistant mCRPC
We hear that an investigational drug called onvansertib — a so-called polo-like kinase 1 (PLK1) inhibitor — may have benefit in the treatment of men with metastatic, castration-resistant prostate...
View ArticleEarly data from the PEACE-1 trial
The so-called PEACE-1 trial is an ongoing Phase III trial among men diagnosed with de novo metastatic castration-sensitive prostate cancer (mCSPC). The earliest results of this trial are to be...
View ArticleMajor results of Phase III VISION trial announced
Earlier today, Novartis issued a media release giving the major results of the Phase III VISION trial, which compared the effectiveness of 177Lu-PSMA-617+ best standard of care (SOC), as selected by...
View Article
More Pages to Explore .....